Thyroid Cancer Resistance to Chemotherapeutic Drugs via Autocrine Production of Interleukin-4 and Interleukin-10

Giorgio Stassi, Matilde Todaro, Monica Zerilli, Lucia Ricci-Vitiani, Diana Di Liberto, Mariella Patti, Adamaria Florena, Francesca Di Gaudio, Giuseppe Di Gesù, Ruggero De Maria

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

We investigated the mechanisms responsible for the widespread refractoriness to chemotherapeutic drugs observed in thyroid cancers. We show that malignant epithelial cells from papillary, follicular, and anaplastic thyroid carcinomas express high levels of Bcl-2 and Bcl-xL. Exogenous expression of either Bcl-2 or Bcl-xL in normal thyrocytes was sufficient to prevent chemotherapeutic drug-induced cytotoxicity. All of the histological thyroid cancer variants examined produced interleukin-4 (IL-4) and interleukin-10 (IL-10), which increased Bcl-2 and Bcl-xL levels and protected thyroid cells from chemotherapeutic agents. Exposure to neutralizing antibodies against IL-4 and IL-10 resulted in down-modulation of Bcl-2 and Bcl-xL, death of a considerable percentage of thyroid cancer cells, and sensitization of the residual tumor population to cytotoxic drug-induced apoptosis. In conclusion, autocrine production of IL-4 and IL-10 promotes thyroid tumor cell progression and resistance to chemotherapy through the up-regulation of antiapoptotic proteins. Thus, IL-4 and IL-10 may represent new therapeutic targets for the treatment of thyroid cancer.

Original languageEnglish
Pages (from-to)6784-6790
Number of pages7
JournalCancer Research
Volume63
Issue number20
Publication statusPublished - Oct 15 2003

Fingerprint

Thyroid Neoplasms
Interleukin-4
Interleukin-10
Pharmaceutical Preparations
Thyroid Gland
Follicular Adenocarcinoma
Residual Neoplasm
Neutralizing Antibodies
Up-Regulation
Epithelial Cells
Apoptosis
Drug Therapy
Therapeutics
Population
Neoplasms
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Stassi, G., Todaro, M., Zerilli, M., Ricci-Vitiani, L., Di Liberto, D., Patti, M., ... De Maria, R. (2003). Thyroid Cancer Resistance to Chemotherapeutic Drugs via Autocrine Production of Interleukin-4 and Interleukin-10. Cancer Research, 63(20), 6784-6790.

Thyroid Cancer Resistance to Chemotherapeutic Drugs via Autocrine Production of Interleukin-4 and Interleukin-10. / Stassi, Giorgio; Todaro, Matilde; Zerilli, Monica; Ricci-Vitiani, Lucia; Di Liberto, Diana; Patti, Mariella; Florena, Adamaria; Di Gaudio, Francesca; Di Gesù, Giuseppe; De Maria, Ruggero.

In: Cancer Research, Vol. 63, No. 20, 15.10.2003, p. 6784-6790.

Research output: Contribution to journalArticle

Stassi, G, Todaro, M, Zerilli, M, Ricci-Vitiani, L, Di Liberto, D, Patti, M, Florena, A, Di Gaudio, F, Di Gesù, G & De Maria, R 2003, 'Thyroid Cancer Resistance to Chemotherapeutic Drugs via Autocrine Production of Interleukin-4 and Interleukin-10', Cancer Research, vol. 63, no. 20, pp. 6784-6790.
Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M et al. Thyroid Cancer Resistance to Chemotherapeutic Drugs via Autocrine Production of Interleukin-4 and Interleukin-10. Cancer Research. 2003 Oct 15;63(20):6784-6790.
Stassi, Giorgio ; Todaro, Matilde ; Zerilli, Monica ; Ricci-Vitiani, Lucia ; Di Liberto, Diana ; Patti, Mariella ; Florena, Adamaria ; Di Gaudio, Francesca ; Di Gesù, Giuseppe ; De Maria, Ruggero. / Thyroid Cancer Resistance to Chemotherapeutic Drugs via Autocrine Production of Interleukin-4 and Interleukin-10. In: Cancer Research. 2003 ; Vol. 63, No. 20. pp. 6784-6790.
@article{df35f0ba728a4c67bbfc8eee2bbf5ed4,
title = "Thyroid Cancer Resistance to Chemotherapeutic Drugs via Autocrine Production of Interleukin-4 and Interleukin-10",
abstract = "We investigated the mechanisms responsible for the widespread refractoriness to chemotherapeutic drugs observed in thyroid cancers. We show that malignant epithelial cells from papillary, follicular, and anaplastic thyroid carcinomas express high levels of Bcl-2 and Bcl-xL. Exogenous expression of either Bcl-2 or Bcl-xL in normal thyrocytes was sufficient to prevent chemotherapeutic drug-induced cytotoxicity. All of the histological thyroid cancer variants examined produced interleukin-4 (IL-4) and interleukin-10 (IL-10), which increased Bcl-2 and Bcl-xL levels and protected thyroid cells from chemotherapeutic agents. Exposure to neutralizing antibodies against IL-4 and IL-10 resulted in down-modulation of Bcl-2 and Bcl-xL, death of a considerable percentage of thyroid cancer cells, and sensitization of the residual tumor population to cytotoxic drug-induced apoptosis. In conclusion, autocrine production of IL-4 and IL-10 promotes thyroid tumor cell progression and resistance to chemotherapy through the up-regulation of antiapoptotic proteins. Thus, IL-4 and IL-10 may represent new therapeutic targets for the treatment of thyroid cancer.",
author = "Giorgio Stassi and Matilde Todaro and Monica Zerilli and Lucia Ricci-Vitiani and {Di Liberto}, Diana and Mariella Patti and Adamaria Florena and {Di Gaudio}, Francesca and {Di Ges{\`u}}, Giuseppe and {De Maria}, Ruggero",
year = "2003",
month = "10",
day = "15",
language = "English",
volume = "63",
pages = "6784--6790",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Thyroid Cancer Resistance to Chemotherapeutic Drugs via Autocrine Production of Interleukin-4 and Interleukin-10

AU - Stassi, Giorgio

AU - Todaro, Matilde

AU - Zerilli, Monica

AU - Ricci-Vitiani, Lucia

AU - Di Liberto, Diana

AU - Patti, Mariella

AU - Florena, Adamaria

AU - Di Gaudio, Francesca

AU - Di Gesù, Giuseppe

AU - De Maria, Ruggero

PY - 2003/10/15

Y1 - 2003/10/15

N2 - We investigated the mechanisms responsible for the widespread refractoriness to chemotherapeutic drugs observed in thyroid cancers. We show that malignant epithelial cells from papillary, follicular, and anaplastic thyroid carcinomas express high levels of Bcl-2 and Bcl-xL. Exogenous expression of either Bcl-2 or Bcl-xL in normal thyrocytes was sufficient to prevent chemotherapeutic drug-induced cytotoxicity. All of the histological thyroid cancer variants examined produced interleukin-4 (IL-4) and interleukin-10 (IL-10), which increased Bcl-2 and Bcl-xL levels and protected thyroid cells from chemotherapeutic agents. Exposure to neutralizing antibodies against IL-4 and IL-10 resulted in down-modulation of Bcl-2 and Bcl-xL, death of a considerable percentage of thyroid cancer cells, and sensitization of the residual tumor population to cytotoxic drug-induced apoptosis. In conclusion, autocrine production of IL-4 and IL-10 promotes thyroid tumor cell progression and resistance to chemotherapy through the up-regulation of antiapoptotic proteins. Thus, IL-4 and IL-10 may represent new therapeutic targets for the treatment of thyroid cancer.

AB - We investigated the mechanisms responsible for the widespread refractoriness to chemotherapeutic drugs observed in thyroid cancers. We show that malignant epithelial cells from papillary, follicular, and anaplastic thyroid carcinomas express high levels of Bcl-2 and Bcl-xL. Exogenous expression of either Bcl-2 or Bcl-xL in normal thyrocytes was sufficient to prevent chemotherapeutic drug-induced cytotoxicity. All of the histological thyroid cancer variants examined produced interleukin-4 (IL-4) and interleukin-10 (IL-10), which increased Bcl-2 and Bcl-xL levels and protected thyroid cells from chemotherapeutic agents. Exposure to neutralizing antibodies against IL-4 and IL-10 resulted in down-modulation of Bcl-2 and Bcl-xL, death of a considerable percentage of thyroid cancer cells, and sensitization of the residual tumor population to cytotoxic drug-induced apoptosis. In conclusion, autocrine production of IL-4 and IL-10 promotes thyroid tumor cell progression and resistance to chemotherapy through the up-regulation of antiapoptotic proteins. Thus, IL-4 and IL-10 may represent new therapeutic targets for the treatment of thyroid cancer.

UR - http://www.scopus.com/inward/record.url?scp=0142219885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142219885&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 6784

EP - 6790

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 20

ER -